Kodiak Sciences
Clinical trials sponsored by Kodiak Sciences, explained in plain language.
Kodiak Sciences
KOD
NASDAQ
Ophthalmology biotech focused on retinal disease treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye drug aims to restore vision in inflammatory swelling Results expected Feb 2027 (estimated) May already have reported ↗ 🚀 Make-or-break
- New eye drug aims to restore vision in Inflammation-Related swelling Results expected Apr 2027 (estimated) May already have reported ↗ 🚀 Make-or-break